This is important because there is a high burden of CVD among people with diabetes, and, with ageing of the population, stroke in particular is becoming more frequent among people with type 2 diabetes [20]; these are outcomes that increased uptake of GLP-1 RAs could affect. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.